DK1492539T3 - Statin-terapi til forögelse af kognitiv funktion - Google Patents
Statin-terapi til forögelse af kognitiv funktionInfo
- Publication number
- DK1492539T3 DK1492539T3 DK03745196T DK03745196T DK1492539T3 DK 1492539 T3 DK1492539 T3 DK 1492539T3 DK 03745196 T DK03745196 T DK 03745196T DK 03745196 T DK03745196 T DK 03745196T DK 1492539 T3 DK1492539 T3 DK 1492539T3
- Authority
- DK
- Denmark
- Prior art keywords
- cognitive function
- statin
- statin therapy
- enhance cognitive
- galantamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36928502P | 2002-04-02 | 2002-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1492539T3 true DK1492539T3 (da) | 2006-10-30 |
Family
ID=28675573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03745196T DK1492539T3 (da) | 2002-04-02 | 2003-03-28 | Statin-terapi til forögelse af kognitiv funktion |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1492539B1 (uk) |
| JP (1) | JP2005525391A (uk) |
| KR (1) | KR100986194B1 (uk) |
| CN (1) | CN100528164C (uk) |
| AT (1) | ATE331523T1 (uk) |
| AU (1) | AU2003226753B2 (uk) |
| BR (1) | BR0308293A (uk) |
| CA (1) | CA2480275C (uk) |
| CY (1) | CY1105545T1 (uk) |
| DE (1) | DE60306503T2 (uk) |
| DK (1) | DK1492539T3 (uk) |
| EA (1) | EA013069B1 (uk) |
| ES (1) | ES2268393T3 (uk) |
| HK (1) | HK1079688A1 (uk) |
| IL (2) | IL164317A0 (uk) |
| MX (1) | MXPA04009535A (uk) |
| NO (1) | NO20044698L (uk) |
| NZ (1) | NZ536111A (uk) |
| PL (1) | PL211160B1 (uk) |
| PT (1) | PT1492539E (uk) |
| UA (1) | UA79605C2 (uk) |
| WO (1) | WO2003082298A1 (uk) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
| CA2562069A1 (en) * | 2004-04-14 | 2005-10-27 | Warner-Lambert Company Llc | Therapeutic combination for treatment of alzheimers disease |
| EP1604686A1 (en) * | 2004-06-08 | 2005-12-14 | Axonyx, Inc. | Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression |
| GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| CA2664421A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Hmg coa reductase mediated modulation of neurogenesis |
| TWI432195B (zh) | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| US20160303146A1 (en) * | 2013-12-13 | 2016-10-20 | David A. TABACZYNSKI | Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders |
-
2003
- 2003-03-28 PL PL371551A patent/PL211160B1/pl unknown
- 2003-03-28 BR BR0308293-8A patent/BR0308293A/pt not_active IP Right Cessation
- 2003-03-28 WO PCT/EP2003/003324 patent/WO2003082298A1/en active IP Right Grant
- 2003-03-28 DK DK03745196T patent/DK1492539T3/da active
- 2003-03-28 UA UA20040806803A patent/UA79605C2/uk unknown
- 2003-03-28 ES ES03745196T patent/ES2268393T3/es not_active Expired - Lifetime
- 2003-03-28 EA EA200401295A patent/EA013069B1/ru not_active IP Right Cessation
- 2003-03-28 IL IL16431703A patent/IL164317A0/xx unknown
- 2003-03-28 CN CNB038073854A patent/CN100528164C/zh not_active Expired - Fee Related
- 2003-03-28 DE DE60306503T patent/DE60306503T2/de not_active Expired - Lifetime
- 2003-03-28 CA CA2480275A patent/CA2480275C/en not_active Expired - Fee Related
- 2003-03-28 AU AU2003226753A patent/AU2003226753B2/en not_active Ceased
- 2003-03-28 JP JP2003579835A patent/JP2005525391A/ja active Pending
- 2003-03-28 PT PT03745196T patent/PT1492539E/pt unknown
- 2003-03-28 NZ NZ536111A patent/NZ536111A/xx not_active IP Right Cessation
- 2003-03-28 AT AT03745196T patent/ATE331523T1/de active
- 2003-03-28 MX MXPA04009535A patent/MXPA04009535A/es active IP Right Grant
- 2003-03-28 EP EP03745196A patent/EP1492539B1/en not_active Expired - Lifetime
- 2003-03-28 KR KR1020047013127A patent/KR100986194B1/ko active IP Right Grant
-
2004
- 2004-09-28 IL IL164317A patent/IL164317A/en not_active IP Right Cessation
- 2004-10-29 NO NO20044698A patent/NO20044698L/no not_active Application Discontinuation
-
2005
- 2005-12-21 HK HK05111808.4A patent/HK1079688A1/xx not_active IP Right Cessation
-
2006
- 2006-09-27 CY CY20061101397T patent/CY1105545T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL164317A (en) | 2010-04-29 |
| PL211160B1 (pl) | 2012-04-30 |
| CA2480275C (en) | 2011-08-16 |
| PT1492539E (pt) | 2006-11-30 |
| CN1642555A (zh) | 2005-07-20 |
| WO2003082298A1 (en) | 2003-10-09 |
| MXPA04009535A (es) | 2005-01-25 |
| HK1079688A1 (en) | 2006-04-13 |
| EP1492539B1 (en) | 2006-06-28 |
| KR20040096608A (ko) | 2004-11-16 |
| CN100528164C (zh) | 2009-08-19 |
| ATE331523T1 (de) | 2006-07-15 |
| EP1492539A1 (en) | 2005-01-05 |
| UA79605C2 (en) | 2007-07-10 |
| BR0308293A (pt) | 2004-12-28 |
| DE60306503D1 (de) | 2006-08-10 |
| NO20044698L (no) | 2004-10-29 |
| EA200401295A1 (ru) | 2005-02-24 |
| KR100986194B1 (ko) | 2010-10-07 |
| DE60306503T2 (de) | 2007-06-21 |
| AU2003226753A1 (en) | 2003-10-13 |
| JP2005525391A (ja) | 2005-08-25 |
| ES2268393T3 (es) | 2007-03-16 |
| CY1105545T1 (el) | 2010-07-28 |
| PL371551A1 (en) | 2005-06-27 |
| NZ536111A (en) | 2006-03-31 |
| AU2003226753B2 (en) | 2007-06-28 |
| EA013069B1 (ru) | 2010-02-26 |
| IL164317A0 (en) | 2005-12-18 |
| CA2480275A1 (en) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
| ATE269846T1 (de) | N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
| CY1105545T1 (el) | Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| DE602004031631D1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
| BG105342A (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
| ATE404192T1 (de) | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration | |
| EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE | |
| ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| DK0707477T3 (da) | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo | |
| HUP0300043A2 (en) | Method and composition for the treatment of pain | |
| DE60122764D1 (de) | Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen | |
| WO2003066806A3 (en) | Therapeutic use of aziridino compounds | |
| ATE334675T1 (de) | Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole | |
| ATE353221T1 (de) | Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa |